OXFORD, United Kingdom and MARLBOROUGH, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces the release of the T-SPOT Discovery SARS-CoV-2 test kit.
First quarter revenue of $13.9 million, a decrease of 6% compared to prior year period, due to the impact of COVID-19 in China Gross margins expanded 270bps to 74% Ended the quarter with $166 million of cash and cash equivalents OXFORD, United Kingdom and MARLBOROUGH, Mass., May 05, 2020 (GLOBE
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2020 financial results before the open of the market on
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that it has successfully obtained re-registration of the T-SPOT. TB test in China.
Fourth quarter 2019 revenue of $18.1 million, an increase of 18% compared to the prior year period Fourth quarter 2019 gross margin of 78.3%, an increase of 410 basis points from the prior year period Fourth quarter 2019 net loss of $1.6 million, as compared to a pro forma (see tables below) net
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the Cowen and Company 40 th Annual Health
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2019 financial results before the open of the
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announces two ground-breaking publications in Clinical Infectious Diseases (CID) on the performance of T-SPOT.
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced they are planning a new initiative to commemorate the coming World Tuberculosis Day, bring the
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the 38th Annual J.P.
Harnessing the power of T cell measurement
